tiprankstipranks
Tenax Therapeutics (TENX)
NASDAQ:TENX
US Market
Holding TENX?
Track your performance easily

Tenax Therapeutics (TENX) Income Statement

542 Followers

Tenax Therapeutics Income Statement

Last quarter (Q2 2024), Tenax Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Tenax Therapeutics's net income was $-3.58M. See Tenax Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 10.93M$ 8.23M$ 11.05M$ 32.73M$ 9.87M$ 8.56M
Operating Income
$ 3.12M$ 8.23M$ -11.05M$ -32.73M$ 9.87M$ -8.56M
Net Non Operating Interest Income Expense
$ 363.87K$ -23.97K$ -4.44K$ -949.00$ 1.63K-
Other Income Expense
$ 117.19K$ 547.24K$ 9.19K$ -254.76K$ -528.00$ -160.96K
Pretax Income
$ -10.69M$ -7.71M$ -11.05M$ -32.47M$ -9.88M$ -8.39M
Tax Provision
-$ -7.15K$ 218.20K$ -73.00$ -194.56K-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -8.24M$ -7.71M$ -11.05M$ -32.47M$ -9.85M$ -8.39M
Basic EPS
$ -11.35$ -31.04-$ -2.53K$ -2.13K-
Diluted EPS
$ -11.35$ -31.04-$ -2.53K$ -2.13K$ -27.00
Basic Average Shares
---$ 12.86K$ 4.63K$ 309.77K
Diluted Average Shares
---$ 12.86K$ 4.63K$ 309.77K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.93M$ 8.23M$ 11.05M$ 32.73M$ 9.87M$ 8.56M
Net Income From Continuing And Discontinued Operation
$ -8.24M$ -7.71M$ -11.05M$ -32.47M$ -9.85M$ -8.39M
Normalized Income
$ -9.09M--$ -32.47M--
Interest Expense
------
EBIT
$ -1.29M$ -7.69M$ -11.04M$ -32.47M$ -9.85M$ -8.39M
EBITDA
$ -1.29M$ -7.69M$ -10.93M$ -32.36M$ -9.74M$ -8.29M
Currency in USD

Tenax Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis